← Search & browse all drugs

omoconazole

G01AF16

Forms & Strengths

Vaginal suppositories: 150 mg, 300 mg
Vaginal cream: 1%
Topical cream: 1%

Adult Dosing

Vulvovaginal candidiasis (suppositories): 150 mg daily for 3 days or 300 mg as a single dose
Vulvovaginal candidiasis (cream): 5 g of 1% cream inserted intravaginally daily for 7 days
Dermatomycoses (topical cream): Apply to affected areas 1-2 times daily for 2-4 weeks

Pediatric Dosing

Safety and efficacy in pediatric patients under 18 years have not been well established
Use in adolescents should follow adult dosing if post-menache, but clinical data are limited

Indications

Treatment of vulvovaginal candidiasis
Treatment of superficial dermatomycoses and cutaneous fungal infections

Mechanism of Action

Broad-spectrum imidazole antifungal agent
Inhibits fungal cytochrome P450-dependent enzyme lanosterol 14-alpha-demethylase
Blocks conversion of lanosterol to ergosterol, leading to increased fungal cell membrane permeability and lysis

Contraindications

Hypersensitivity to omoconazole, other imidazole antifungals, or any excipients in the formulation
First trimester of pregnancy (precautionary measure for systemic absorption from vaginal products)

Adverse Reactions

Local burning, irritation, or itching at the application or insertion site
Erythema and contact dermatitis
Rare systemic allergic hypersensitivity reactions

Drug Interactions

Potential degradation of latex barrier contraceptives (condoms, diaphragms) by lipid excipients in vaginal formulations
Minimal systemic absorption via topical/vaginal routes, making systemic drug-drug interactions unlikely but theoretically possible with potent CYP3A4 inhibitors/inducers if absorbed significantly

Curated Content: Needs Vetting Before Put to Clinical Use